Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/09/2022* -- Results Q2 2022 -- -0.13 --
05/09/2022 -- Results Q1 2022 0.00 -0.10 96.00%
02/28/2022 -- Results Q4 2021 0.04 -0.05 188.1%
11/08/2021 -- Results Q3 2021 0.54 -0.07 873.9%
08/09/2021 -- Results Q2 2021 -0.15 -0.07 -130.8%
05/10/2021 -- Results Q1 2021 -0.35 -0.09 -288.9%
05/10/2021 08:00 EST Earnings Call Q1 2021 -- -- --
03/15/2021 -- Results Q4 2020 -0.07 -0.11 35.82%
*Estimated Date/Time

Earnings

Next Report Date 08/09/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/09/2022
Beat/Miss Upgrade
Return Since 75.40%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The company plans to conduct an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in connection with the potential resubmission of a BLA.
URL https://www.sesenbio.com
Investor Relations URL N/A
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Aug. 09, 2022 (est.)
Last Earnings Release May. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-74.66%
-36.54%
-57.54%
75.09%
-26.76%
29.81%
-39.63%
0.33%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.31%
-2.61%
44.35%
226.8%
-54.95%
-54.20%
-51.99%
-78.54%
-49.55%
35.55%
-29.98%
-1.53%
-46.08%
-30.87%
-2.21%
16.59%
27.73%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
-3.01%
--
--
24.37%
38.45%
2.00%
3.01%
-39.64%
-87.75%
As of June 24, 2022.

Profile

Edit
Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The company plans to conduct an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in connection with the potential resubmission of a BLA.
URL https://www.sesenbio.com
Investor Relations URL N/A
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Aug. 09, 2022 (est.)
Last Earnings Release May. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter SESN Tweets